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1. Introduction
Congenital hypothyroidism is the most frequent congenital endocrine disorder and prevent‐
able cause of mental retardation. The remarkable irreversible mental damage can be avoided
by the replacement therapy introduced before the age of 3 weeks. Therefore a screening
program implemented in the early seventies to pick up the affected babies on the first weeks
of life [1,2]. After pilot studies started in 1977 a national neonatal TSH screening program was
introduced in Hungary in 1982 [3]. It has continued in two centers from 1984 covering the
whole country (50-50 % of the expected newborns were assigned to one lab). Patients screened
and confirmed as CH were followed-up at the endocrine outpatient clinics. Replacement was
adjusted according to the laboratory results and somatic-mental development of the child. The
authors (two pediatric endocrinologists and one psychologist) have worked together in this
project throughout 26 years in one of these centers. They present their experiences with the
screening program and the endocrine/psychological follow-up gained during this period
discussing the results with literature data.
The widely known incidence data on congenital hypothyroidism before the introduction of
neonatal screening originate from the North European countries: 1 to 6000-10000 [4-6].
Nowadays when the usage of the national language is increasingly accepted in authentic
translation at the international forums the Hungarian contribution may be interesting. The
Thyroid Work Group of Hungarian Pediatric Institute collected five years incidence data
(1966-70) from the pediatricians all over the country and “… 40/year new hypothyroid children
were reported”. The birthrate was 160.000/year that time, so the incidence was calculated
1:4000, published in Hungarian in 1972 [7]. This numerical value almost corresponds to the
data experienced by the neonatal screening.
According to the recent data the incidence of congenital hypothyroidism varies from 1:1000 to
1:3500 life births depending on the iodine sufficiency, demographic and other unknown factors
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as well as on laboratory methods and screening practice. Several work groups noted a progres‐
sively rise since the early 1990s both in America and Europe [8-16], however the question was
raised with reason: “Was this increasing incidence real … or was … an artifact, explained by
modifications of screening programs such as a change in test cutoffs?” (LaFranchi 2011; [13].
According to a convincing Canadian study the incidence of thyroid dysgenesis, which form is
more than 80 % within the CH, has remained relatively stable over the last decades [9,15].
Demographic factors were “suspected” to be responsible for this phenomenon [8] but it was not
confirmed as a complete explanation [9]. The changes in test cutoffs [13,14] or simply the used
different laboratory and screening methods in certain centres [17] might be also the first
candidates behind the increasing incidence rate in some screening programs. These data
“highlight the need for consensus development regarding the diagnosis and treatment of
congenital hypothyroidism” according to Rapaport’s commentary [18] to one of these reports
[12]. And indeed, recently (November 2011) recommendations were prepared at the ESPE
consensus meeting (complete version is in press) for orientation relating to the screening,
investigation, treatment, long terms outcomes and genetic/antenatal diagnosis in CH [19].
In Hungary the screening program is based on primary TSH determination and the overall
incidence of CH is 1:3316, namely 413 cases were diagnosed out of 1,369.503 newborns screened
between 1982 and 2007 in our Screening Center. The annual incidence is relatively constant
(Figure 1.). Opposite to primary T4/FT4 measurement with backup TSH determination it was
not necessary to change the cutoff levels of TSH for increasing the sensitivity and other
conflicting factors could be avoided, namely the low FT4 levels of preterm babies and obtaining
the blood specimens remarkably earlier.
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Figure 1. Annual incidence of congenital hypothyroidism
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Most of the cases detected in newborn age have permanent hypothyroidism caused by
abnormal thyroid gland development (dysgenesis) or that of inborn error of thyroid hormo‐
nogenesis (dyshormonogenesis). Thyroxine-binding globulin (TBG) deficiency occurs in 1 to
9000 life births, while congenital central hypothyroidism (TSH and/or TRH deficiency) occurs
in less than 1:20000-100000. Transient hypothyroidism may occur because of delay in matu‐
ration of the hypothalamic-pituitary-thyroid axis, both iodine deficiency and excess, dysfunc‐
tion of the mother-placenta-fetal unit or the effect of medication used on the intensive care
unit. Both monoallelic and biallelic mutations in DUOX2 gene result transient CH reported
recently [20,21]. Permanent CH patients need a life-long treatment while transient cases can
quit of replacement after recovery of thyroid function.
As the postnatal development of the nervous system is thyroid hormone dependent up to 2-3
years none of the patient were put on higher risk by suspend the therapy to early therefore the
revision of the neonatal diagnosis was postponed above the age of 2-3 years. Classifying the
disorder as permanent or transient was obtained on abnormal or normal hormone levels after
withdrawal of levothyroxine replacement. Before 2 years of age the following course of the
disease was suspicious for transient dysfunction of the thyroid. Shortly after the introduction
of replacement therapy TSH normalized and never increased above the upper limit parallel
with decreasing demand of levothyroxine to keep T4/FT4 in the reference range. In 21 patients
out of 291 substituted infants we could simply withdraw the replacement and the TSH
remained normal.
Above the age of 3 years a T3 withdrawal test was performed in 197 children to reconsider the
diagnosis of CH. We applied the same method for all patients: L-T4 was shifted to L-T3 for 3
weeks, which has a shorter half-life. After one week L-T3 was also stopped, patients were off-
treatment altogether for one week. At the end of the 4th week presenting a normal thyroid
function test is considered to be a transient hypothyroid case. Five out of 197 patients tested
have proven transient CH. The total number of children reached 3 years of age and who were
old enough for T3 withdrawal test were 310, which give the overall transient CH rate as 8.4 %
(21+5/310).
2. Methodology
From the very beginning up to the end of 2007 we used a primary TSH screen and a secondary
serum thyroid hormone measurement to confirm the abnormal TSH results. A drop of whole
blood was obtained and dried on filter paper between the ages of 3-5 days. Samples were sent
to the assigned screening laboratory via mail. Measurement of TSH was performed after an
elution process using a home-developed RIA until 1993 [21,22]. Cessation of the cheap anti‐
body supply forced us to buy commercial kits changing for DELFIA, LIA, IRMA and ELISA
methods. All tests offered narrower measuring ranges and cutoff values became more precise.
The algorithm for selection of specimen for further evaluation was very simple. Samples below
the cutoff level (25 μU/ml later on 20 μU/ml) were considered as normal, between the range
25(later on 20)-50 as suspected positive and above 50μU/ml as true positive. Technical errors
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were ruled out by repeated measurement from the blood spot and only samples above the cutoff
limit were recognized and infants were called to visit us immediately. Physical examination and
blood sample were taken for peripheral thyroid hormones and TSH measurement from the
serum. The diagnosis of CH was confirmed by low T4/FT4, T3/FT3 levels and elevated TSH.
2.1. Etiology
Almost 95% of cases born with CH have primary hypothyroidism reflecting peripheral defects
and less than 5% has secondary/tertiary hypothyroidism results from lack of TSH and/or TRH
production. Both the presentation and the sequel of the congenital central hypothyroidism are
less severe although most commonly it is part of a disorder causing congenital hypopituitar‐
ism. Several imaging methods are suitable to describe the position and size of the thyroid.
Localization or absence of the gland helps to differentiate dysgenesis and dyshormonogenesis
in CH patients.
I123 scan is optimal to test the newborn babies for possible developmental defect of the thyroid
gland before replacing them but it was not available for us. During replacement therapy the
background of thyroid dysfunction was tested using different imaging techniques. Ultraso‐
nography is a non-invasive method but requires a baby-head for apparent description of a tiny
or absent gland. Thyroid scintigraphy is a more precise but invasive method requiring an
unreplaced situation. Scintigraphy was performed in 182 cases combined with T3-withdrawal
test. Thyroid dysgenesis occurred in 84% (agenetic: 47%, ectopic lingual: 28%, hypoplastic:
9%), an enlarged thyroid was seen in 6% and a normal-sized eutopic gland – so-called “thyroid
in situ” [12,13] – in 10%.
Further distinction of etiology is offered by molecular genetics. Several genes involved in
thyroid ontogenesis and in normal function of it. An abnormal expression of the thyroid
specific genes can be manifested in different phenotype, which is summarized in Table 1.
Gene Chromosomeregion
Role of gene in organogenesis/
protein function
Phenotype (by
morphology or
function)
Associated disorders
DYSGENESIS
TITF1/NKX2.1 14q13 Development of both follicularand C-cells
Aplasia or
Hemiagenesis or
Hypoplasia (with or
without ectopy)
Choreoathetosis, RDS,
pulmonary disease
PAX8 2q12-q14 Thyroid follicular cell development Renal agenesis
TITF2/FOXE1 9q22 Migration of thyroid precursorcells
Cleft palate, choanal
atresia, bifid epiglottis,
spiky hair (Bamforth-
Lazarus sy.)
GNAS1 20q13.2 Signalling protein Resistance tothyrotropin
Osteodystrophy
(hereditary Albright sy.)
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Gene Chromosomeregion
Role of gene in organogenesis/
protein function
Phenotype (by
morphology or
function)
Associated disorders
TSHR 14q31 Thyroid differentiationThyrotropin receptor
Hypoplasia (without
ectopy) Resistance to
thyrotropin
-
INBORN ERROR OF THYROID HORMONOGENESIS
TITF1, PAX8, TITF2/
FOXE1 See above
During later stages: Regulation of
thyroid specific gene expression
Enlarged thyroid gland
-
TPO 2p25 Thyroid differentiation Iodideorganification -
TG 8q24.2-q24.3 Thyroid differentiation Structuralprohormone -
NIS 19p13.2-p12
Iodide transport from the blood
into thyroid cell (basal
membrane)
-
PDS 7q31
Iodide transport from thyroid cell
to follicular lumen (apical
membrane)
Sensorineural deafness
(Pendred sy.)
DUOX1/THOX1
DUOX2/THOX2 15q15.3 Thyroidal H2O2 generation -
DUOXA2 15q21.1
IYD/DEHAL1 6q24-q25 Deiodination for iodide recycling -
THYROID HORMONE TRANSPORTER DEFECT
MCT8 Xq13.2 Transmembrane T4, T3, rT3, T2transport Thyroid hormone
resistance
Severe neurological
abnormalities (Allan-
Herndon-Dudley sy.)
THRB 3p24.3 Nuclear thyroid hormonereceptor
Hyperactivity, learning
disability
SBP2 9q22.2 Synthesis of selenoproteins Abnormal TFT Delayed puberty (?)
IMPAIRED HYPOTHALAMIC-PITUITARY-THYROID AXIS
LHX3 9q34.3 Early pituitary development
Secondary/tertiary
hypothyroidism
CPHD, pituitary mass,
rigid cervical spine
LHX4 1q25 CPHD, sella turcicadefect
PROP1 5q Expression of all pituitary celllineage CPHD, pituitary mass
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Gene Chromosomeregion
Role of gene in organogenesis/
protein function
Phenotype (by
morphology or
function)
Associated disorders
POU1F1 3p11 Generation and cell-typespecification GH, PRL deficiency
HESX1, PHF6 3p21.2-p21.1 Forebrain, midline and pituitarydevelopment
Septo-optic dysplasia,
CPHD, epilepsy
TRHR 8q23 TRH receptor -
TSHB 1p13 TSH β subunit -
OTHER
DUOX2/THOX2
DUOX/DUOXA 15q15.3 Partial defect in H2O2 production Transient CH -
CH= Congenital hypothyroidism, CPHD = Combined pituitary hormone deficiency, GH = Growth hormone, PRL =
Prolactine, RDS = Respiratory distress sy, TFT = Thyroid function test
Table 1. Thyroid specific genes involved in congenital hypothyroidism [23-39]
A cohort of 58 patients was analyzed for PAX8 (exon2 and exon3) mutation. Genetic screening
did not reveal any mutation on the PAX8 gene in children with thyroid dysgenesis. It supports
the recent notion that non-syndromic thyroid dysgenesis is rather a heterogeneous disease
than a monogenetic one. Up to now the exact etiology of CH remained unknown for the great
majority of the cases. More candidate genes have been verified in syndromic CH patients as
distinct gene loci can be connected to distinct clinical feature. Analyzing our cohort congenital
malformations were found in 45 cases (Table 2.) and concomitant disorders in 46 cases out of
210 CH patients (Table 3) [40]. Phenotypes specific gene on selected CH patients with associ‐
ated disorders should be analyzed to gain more information on fetal thyroid development.
Recently Park and Chatterjee proposed an algorithm for investigating the genetic basis of
congenital hypothyroidism [41].
Malformations, syndromes Male Female Cytogenetic location
Congenital heart disease 6 3
Renal malformation 5
Urogenital malformation 11 2
Musculoskeletal malformation 3
Scoliosis 2 1
CNS malformation 1 1
Dysmorphic auricle/face 2 2
Pulmonary fibrosis 1
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Malformations, syndromes Male Female Cytogenetic location
DiGeorge sy. 1 22q11
Kabuki make-up sy. 1 8p22-23.1
Marfan sy. 1 15q21.1
Mayer-Rokitansky-Küster-Hauser sy. 2 1p35
CNS = central nervous system
Table 2. Congenital malformations found in CH patients (45/210)
Impaired function Male Female
Delayed speech development 3 4
Stammer 2
Behavioral problem 3 4
Delayed motor development 1 1
Disturbed motor coordination 2 2
Nocturnal enuresis 7
Strabismus 3 1
Congenital nystagmus 1
GORD 1 2
Epilepsy 1
Malignancy 2
Serious infection 2
T1DM 1
Angioedema 1
GORD = gastro-oesophageal reflux disease, T1DM = type 1 diabetes mellitus
Table 3. Concomitant disorders found in CH patients (46/210)
2.2. Clinical signs
The classical picture of CH with characteristic clinical features develops by the age of three
months with irreversible neurological damage. Non-specific signs and symptoms can be
noticed during the first weeks of life, which help to set the diagnosis of CH in screened but not
confirmed newborns. During the first 10 years of screening program all newborns identified
by an abnormal TSH were admitted to the hospital and were assessed by history and complete
physical examination. More than 10 unspecific symptoms and history data recorded of 87
suspected babies were analysed to identify any factors that could predict congenital hypo‐
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thyroidism. Based on confirmatory laboratory results 67 babies out of 87 proved to have CH
(true positive or CH group) and 20 was false positive (reference group). Between the two
groups 8 parameters (opened posterior fontanel, umbilical hernia, dry skin, enlarged tongue,
constipation, laziness, wide nasal bridge, and prolonged jaundice) were found to have
significant differences by linear discriminant analysis that were ranked and weighted for
scoring. An additional score was calculated from the blood-spot TSH namely the quotient of
measured TSH and the cutoff limit for normal thyrotropin. Figures above 6 were correct for
predicting CH in 99% of cases. This score system developed (Table 4.) advises the clinicians to
pick up and replace the affected babies earlier than 3 weeks of age [22,42].
Clinical sign Score Clinical sign Score
Opened posterior fontanel 2 Constipation 1
Umbilical hernia 2 Laziness 1
Dry skin 2 Wide nasal bridge 1
Enlarged tongue 1 Prolonged jaundice 1
Blood spot TSH: Quotient of measured and cutoff limit for normal 1
Cutoff value for predicting CH "/> 6
Table 4. Score system for predicting congenital hypothyroidism using primary TSH measurement
2.3. Endocrine and psychological care
2.3.1. Thyroid hormone replacement
The timing of T4-level’s normalization is crucial to the neuropsychological development
therefore the first aim of the neonatal screening programs is to reach the earliest start of the
hormone replacement. At the beginning the intervals between the birth and start of T4
replacement were reduced in length as follows: in 1985: 25 ± 5 days, in 1987: 20 ± 9 and in 1990
18 ± 9 days. This length of time improved to ≤ 14 days on average after the introduction of one-
day TSH assays and successful education of the personnel involved.
Concerning the dosage and the formulation of thyroid hormone replacement let us call to mind
some of our former results, namely in the 1980s both lower and higher thyroxin doses were
applied [43–49]. In our early study [22,50] the higher L-T4 dose was found to be more effective
than the lower one (Table 5). It was confirmed recently also by the Glasgow-group recom‐
mending the 50 μg initial dose on the basis of their results in 314 children with CH [51]. In our
program 10-15 μg/kg as an initial dose is used since the middle eighties [22,42].
At the beginning of our TSH-screening pilot studies (in the early seventies) the synthetic L-
T4 preparations were not available in Hungary, therefore the thyroid hormone replacement
was started with oral administration of thyroid extract (thyreoidea sicca: Thyranon, Organon).
Later on we changed to the L-T4 monotherapy and according to our first impressions the
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Thyranon proved to be more effective at least regarding the decrease of TSH level [22,50]. It
was confirmed in our systematic study but the increase of T3 level was also detectable (Table 6.)
T4 (μg/dl) T3 (ng/ml) TSH (mIU/L)
at start at control at start at control at start at control
Thyranon (T3+T4) n =
21 3,0 ± 2,6 11,3 ± 4,2 1,15 ± 0,51 3,07 ± 1,70 73,84 ± 10,49 13,16 ± 26,35
L-Thyroxin (T4) n= 22 3,3 ± 2,9 13,0 ± 3,9 1,3 ± 0,77 2,2 ± 0,65 75,19 ± 16,30 29,10 ± 31,41
Thyranon⇒L-T4 n = 19
before after before after before after
change of replacement
10,4 ± 3,2 11,9 ± 2,4 2,63 ± 0,96 2,03 ± 0,66 13,75 ± 22,21 14,13 ± 16,79
Normal values: T4: 9,0-15,0 (newborn: -20,0) μg/dl; T3: 1,5-3,5 (newborn: -4,0) ng/ml;
TSH: 0,5-5,0 (newborn: -20,0) mIU/L
Table 6. Changes of thyroid parameters on T4 or T4 + T3 replacement
At that time our conclusion was: “these results confirm the suggestion that T3 may play a more
important role than T4 in regulating the serum TSH concentration” [50].
One of the main goals of thyroid hormone replacement in congenital hypothyroidism is to
restitute the biochemical euthyroidism (the TSH and thyroid hormone levels into the reference
ranges) to avoid the prolonged hyperthyroxinemia and the permanent overproduction (or
suppression) of thyrotropin. The most important period to monitor the adequate thyroid
hormone replacement is the first three years of life to ensure optimal somatic and psycho‐
neurological development. Our practice harmonize the recent recommendation: follow-up
Number of children 22 13
Dose of L-T4 25 μg 6,6 μg/kg 50 μg 13,4 μg/kg
Starting
values
T4 (μg/dl) 3,3 ± 2,9 3,6 ± 3,5
T3 (ng/ml) 1,14 ± 0,77 1,34 ± 0,59
TSH (mIU/L) 75,1 ± 16,3 74,9 ± 10,4
Values at first
visit
T4 (μg/dl) 13,2 ± 3,9 18,9 ± 3,6
T3 (ng/ml) 2,2 ± 0,65 2,09 ± 0,33
TSH (mIU/L) 29,1 ± 31,4 1,0 ± 0,9
Interval (days) 28 ± 35 19 ± 7
Normal values: T4: 9,0-15,0 (newborn: -20,0) μg/dl; T3: 1,5-3,5 (newborn: -4,0) ng/ml;
TSH: 0,5-5,0 (newborn: -20,0) mIU/L
Table 5. Correlation between starting L-T4 dose and changes of thyroid parameters during hormone replacement
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every 1-2 months in the first 6 months, every 2-3 months between 6 months and 3 yrs of age
and every 6-12 months later in childhood [52,53].
There are warning data on the importance of well-organized care of children with CH.
According to a new American publication based on health insurance claims data of 704
children with presumed CH 38 % (!) discontinued replacement of thyroid hormone within the
first 3 yrs of life [54]. In another smaller cohort (140 children) 48,6 % were lost to follow-up (!);
of the 72 patients who were re-evaluated at age 3 yrs, treatment had been stopped without
medical supervision in 15 [55]. The puberty and adolescence are the most critical periods
regarding the compliance in our experience.
In our practice another unexpected alteration has been occurred during the long and contin‐
uous follow-up. In a few cases with stable FT4/TSH relation for many years under gradually
increased L-T4 dose according to the somatic development and TSH-FT4 values, later we
measured elevated TSH despite high FT4 levels almost regularly. On the basis of our good
experience with Thyranon (L-T4 + L-T3) replacement therapy in the 1970s, we tried to normalize
both serum TSH and FT4 level administered combined L-T4 and L-T3 treatment in these
patients. Applying an L-T4/L-T3 dose ratio between 13:1 and 18:1 by weight, this modification
of therapy mostly proved to be successful (one exemplar on Table 7). The dose of L-T4 was
reducible in some other patients. Unfortunately once-daily slow-release formulation of L-T3
[56] was not available for us.
Age (year) TSH (mIU/L) FT4 (pmol/L) FT3 (pmol/L) L-T4 μg/day L-T3 μg/day
12 13,24 19,43 5,1 125 -
14,5 11,25 18,7 5,4 150 -
15 6,59 22,26 5,5 150 -
15,5 9,35 20.18 5,8 150 -
16,5 2,25 11,24 5,8 100 20
16,75 3,30 12,80 9,0 125 10
17 6,05 16,14 5,8 150 10
17,25 2,20 19,96 6,9 150 10
Table 7. Some data from the last six years of an adolescent boy
Recently the use of L-T4 + L-T3 in the treatment of hypothyroidism is one of the ”hot topics” in
thyroidology (see excellent papers [57,58] and “2012 ETA guidelines” [59]), however our
observation is different from those. These children and adolescents do not have hypothyroid
symptoms comparing to the adults (5-10 %) and do have elevated TSH (and FT4) level. The
congenital form of hypothyroidism – as an entity – is not included in the ETA guidelines at all
[59]); it is restricted on adults with autoimmune hypothyroidism or caused by definitive
therapy (radioiodine, surgery). Now we are analysing the data of our patients in this small
cohort.
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2.3.2. Evaluation of the somatic development
The aim of thyroid hormone replacement is to ensure optimal somatic and neuropsychological
development. The evaluation of somatic and psychological parameters is also necessary to
control the quality of compliance, what may be disturbed, – as was mentioned before –
especially in the adolescent period. The hormone parameters are relative “quick variable”. The
state of thyroid hormone supply at the less and less frequent outpatient visits is well reflected
in the somatic development, as “slow variable”.
Somatic development was analyzed using the height and bone age data of 83 prepubertal
children. Height was measured regularly by Harpenden stadiometer and evaluated by
Hungarian reference data [60]. Bone age was also determined repeatedly up to the disappear‐
ance of bone age retardation using the Greulich-Pyle atlas [61]. Bone mineral density (BMD) was
measured by single photon absorptiometer (SPA; Gamma Works, Hungary) in 46 children
(6-17 yrs). Later peripheral quantitative computer tomography (pQCT; XCT2000, Stratec
Electronics, Germany) was introduced to determine radial volumetric total BMD and trabec‐
ular Z-score values of 91 children (6-18 yrs). The results were evaluated comparing with
Hungarian reference data [62,63].
2.3.3. Growth velocity and bone age
The comparison of age and age for height does not show any difference (age: 6,27 ± 2,65 yrs;
age for height: 6,26 ± 2,76 yrs). Bone age was lower than the chronological age (5,73 ± 2,77 yrs;
p = 0). The regression’s line diverges from the theoretical optimum line in the younger age, but
the distribution of the values are almost the same on both sides of the “ideal” line in the older
than 10 year of age, or more convincing some values indicate bone age retardation under 10
years (Figure 2).
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Figure 2. Bone maturation of L-T4 replaced CH patients (n=83)
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The publications report usually good results on somatic growth and pubertal development of
children with CH detected by neonatal screening and supplemented well with L-T4 [64-69].
Our results clearly show that the disappearance of bone age retardation is individual. The bone
age of children with CH catch up their chronological age in different time at latest about ten
years of age.
2.3.4. Bone mineral density
In our first (SPA) study – 0,24 ± 1,24 mean Z-score values were found; below – 2,0 in 3 cases
only. After correction to age for height, one value remained under –2,0 Z-score [62]. However,
SPA may measure false results in growing children (areal BMD; its measure is g/cm2) due to
the change of bone size. To avoid this possibility pQCT (volumetric BMD; its measure is g/
cm3) measurements were carried out later. The mean total BMD Z-score of 28 boys was – 0,19
± 1,18 and the trabecular BMD Z score: + 0,05 ± 0,9, both in the normal range. Similar values
were measured in the group of 63 girls: total Z-score + 0,04 ± 1,15, trabecular Z-scores + 0,1 ±
0,98, but some differences were found in the total density between the younger and older girls
(≤ 11 yr – 0,36 ± 0,9 and > 11 yr + 0,3 ± 1,22). Pathological (< - 2,0) BMD Z-score did not occur at
all among the 28 boys, and only two trabecular density values were in this range among the
63 girls. The total BMD Z-score was found between – 1,0 and – 1,9 in 5 cases in both groups, the
trabecular Z-score value was in this range very rarely (1 and 2 cases respectively).
One of the most important preventive factors of the adult osteoporosis is the attainment of an
optimal peak bone mass. Therefore the importance of the good accretion of bone mineral
content during the childhood and adolescence is generally recognized. Thyroid hormones are
one of the known influencing factors of the BMD. Hyperthyroxinemia can cause bone resorp‐
tion resulting in a decreased bone mass. BMD was found decreased in adolescent females
treated with high doses of L-T4 [70].
In the first pediatric studies did not measure decreased bone mineral content in children with
congenital hypothyroidism by DXA technique [71,72]. Recently slightly decreased BMD values
were published within the normal range [73,74], in one publication by quantitative ultrasound
technique [73]. In spite of the different methodology what we used (pQCT: direct volumetric
method, not mathematically corrected areal one) our conclusion is similar regarding the
development of BMD in children and adolescents with congenital hypothyroidism diagnosed
at neonatal screening and replaced by L-T4. Our results are also very slightly lower compared
to controls, but the Z-score values are practically always within the reference range.
2.3.5. Final height
In a cohort of 98 children (65 girls) the final height (FH) or nearly FH (growth ≤ 1 cm in the last
year) was determined. Results are presented on the table (Table 8.)
The mean value of FH in boys corresponds to the Hungarian reference data and the 3,1 cm
difference in the average of girls does not mean significant deviation. In a detailed presentation
interesting data were published on “prepubertal and pubertal growth, timing and duration of
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puberty and attained adult height” of 30 patients, included 17 FH values [66]. The authors
emphasize the significant positive correlation between the average L-T4 daily dose adminis‐
tered during the first 6 months of treatment and attained height. We cannot confirm this
observation because of our different protocol (uniform L-T4 dosage was used during the last two
decades).
In a Japan publication a greater peak height velocity and pubertal height gain was presented
in their male patients [67]; we also observed some difference between the FH of boys and girls
to the advantage of the boys.
2.3.6. Menarche
Correct data were gained from 50 girls. Their menarche age is 12,38 ± 1,06 yrs, what is the same
as the reference value in Hungary, however the distribution of data is surprising. The mani‐
festation of the first menses happened rather earlier (in 23 girls ≤12 yrs) or later (in 19 girls ≥
13 yrs) than close to the mean (8 only) indicating the relationship between the thyroid hormone
and sexual hormone axes. Italian authors differentiated two groups of girls according to their
menarche age (11,5 ± 0,8 yrs versus 12,6 ± 1,2 yrs) like us but both groups attained normal FH
similarly to our results [68].
3. Evaluation of psychoneurodevelopment
The somatic development is almost perfect in the children with CH detected by neonatal
screening and had optimal thyroid hormone replacement. The same does not apply to their
psychoneurodevelopment.
After the first ten years of our neonatal TSH screening program (117 CH/508.590 newborn) the
IQ was tested in a cohort of 46 children (39 permanent and 7 transient CH; age 3-8 yrs). Al‐
though a normal distribution of IQ values was detected, a strong correlation was observed in 28
children between the IQ and serum thyroglobulin (Tg) level (Tg < 0,3 ng/ml in 3 out of 21 with
IQ > 90 and 4 out of 7 with IQ < 90; p < 0,01 using Yates correction). This early data confirmed the
thesis  [75,76]  that  although there is  some placental  transfer of  thyroid hormones during
pregnancy, it cannot totally prevent the intrauterine neurological damage in athyroidism [77].
Ten years later we presented more detailed results on the neurodevelopment of CH children
[78,79]. The main message is summarized on the next table (Table 9.) The correlation between
the date of diagnosis, serum T4 level before start of replacement, initial L-T4 dose and the IQ
of 58 children (born 1985-95; tested 1993-2000 at age 4,9 ± 2,0 yrs; repeatedly tested 49 of them
Boys (33) Girls (65)
Age (yrs) 17,83 ± 2,56 17,47 ± 2,17
Final height (cm) 177,41 ± 5,77 164,11 ± 6,28
Table 8. Final (and nearly final) height of 98 patients with CH
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at age 8,5 ± 2,5 yrs) were analyzed. According to these data the onset of replacement before 2
weeks of life in the newborns with serum T4 level < 3 μg/dl ensure the best IQ; similar data
are published [46,47,49].
Serum T4 < 3 μg/dl
Start of L-T4 replacement (day)
7-13 14-26
Dose of L-T4 μg/kg/day < 10 "/> 10 < 10 "/> 10
Number of patients 3 3 15 8
IQ values 106,3 ± 8,0 108,7 ± 26,5 101,4 ± 12,2* 101,4 ± 11,4
Serum T4 "/> 3 μg/dl
Start of L-T4 replacement (day)
7-13 14-26
Dose of L-T4 μg/kg/day < 10 "/> 10 < 10 "/> 10
Number of patients 6 5 14 4
IQ values 115,0 ± 6,7 113,6 ± 13,6 103,6 ±8,4 103,8 ± 12,8
* p = 0,05
Table 9. Relationship between some important parameters and the IQ in replaced children with CH
With these experiences we realized the need of regular psychological care. One of us (R.G.)
performs this work continuously connecting the endocrine outpatient clinic. Every patient is
tested at least once a year.
The recently prepared DQ and IQ results are presented on the next table (Table 10).
Age (year) Number of patients DQ/IQ values Test-methods (norm.: 90-110)
< 3 175 99,65 ± 13,0 Brunet-Lésine
3-8 146 104,44 ± 12,7 Binet
8-10 136 106,3 ± 10,59 Binet
14-16 30 93,25 ± 7,22 WISC-IV*
*Wechsler Intelligence Scale for Children 4th ed. (total quotients). The Processing Speed Q: 95,07 ± 12,74; Verbal Q: 92,81
± 11,69; Performance Q: 92,55 ± 14,63 and Working memory Q: 89,92 ± 14,95.
Table 10. Developmental and intelligence quotients
The DQ and IQ test-results of the first three age groups are in the normal range. Some
neurocognitive abilities might be affected in these children (visuospatial-, visuomotor-,
language and speech-, attention and memory).
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If the DQ value tested by Brunet-Lésine method suggests a delay in development, we can intervene
early enough to help the children. A developmental intervention program is prepared for the
children and parents. In these cases the psychoneurological development are regularly control‐
led. The meetings the family are as often as it is possible or necessary in these cases.
The Binet test is rather verbal test of intelligence (not appropriate to recognize the delay of
speech-development, but good for measuring problem-solving, vocabulary employment of
experience). Early intervention is necessary in the case of delay in expressive speech and
difficulties with coordinative movements (danger of difficulties at school!). Learning disability
can be diagnosed in the third class earliest. At the age of 8-10 yrs the Binet test can give
acceptable information on the intellectual development. If there are more than one problem of
different cognitive abilities, that can mean an increased risk from the point of learning
disability. These children have problems with mathematics (not with mechanical reading but
with the reading comprehension). The number of children with disability was 9 in this small
material: reading disability (3), learning disability in mathematics (3) and ADHD (3).
The WISC-IV test was accredited lately, therefore its use started recently. The results of the
first 30 tests (the total IQ and especially the quotients for partial abilities: processing speed-,
verbal-, performance- and working memory quotients) tend to be weaker corresponding to
the international experiences.
The beneficial effect of early start of replacement and the use of higher initial dose is almost
generally accepted. Recently 51 articles were analysed publishing IQ values of children with
CH. Normal values were detected in one third of the reports but in the other papers the IQ
was found significantly lower comparing to controls [80].
The main conclusions: some of the prenatal effects of hypothyroidism may be irreversible
especially in the athyroid babies and may be detected subtle, selective deficits of different
abilities in the children with CH in comparison to appropriate reference groups [81,82]. Despite
these observations the newborns and children with CH may have better psychoneurological
development and long-term outcomes without comparison than before the introduction of the
screening system.
Recently a very remarkable material was published by Leger and co-workers [83] on long-term
health and socio-economic attainment of French young adult (median age: 23,4 yr) patients
with permanent CH detected by neonatal screening between 1978 and 1988 on the basis of self-
reported data by questionnaires. Round 1200 answers were evaluated and compared to data
of controls. Chronic diseases, hearing impairment, visual problems, overweight were found
significantly oftener, moreover socio-economic attainment, health-related quality of life, and
full-time employment were lower or less among the CH patients. As limitation of the study is
given that “outcome data are based on management procedures used early in the history of
the CH screening program” (start of therapy, starting dose etc), however 20,6 % of their patients
had abnormal serum TSH values (with median of 12,0 mIU/L) determined within 2 yr of the
questionnaire study. Therefore one of the author’s conclusions is that the patient’s care should
modify “to improve compliance with treatment and medical care during the transition from
pediatric to adult services” [83].
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4. Conclusion
In the era before the neonatal thyroid screening 1:4000 incidence of hypothyroidism was
calculated in Hungary on the basis of five years (1966-70) survey by questionnaires from
pediatricians. The results of TSH screening (413 permanent CH/1,369.503 newborn = 1:3316)
confirmed it during the last quarter of a century (1982-2007). The technique and the incidence
did not change significantly in this long period.
Transient form of CH was diagnosed in 8,4 % (26/310). Thyroid scintigraphy in 182 cases
showed the following results: dysgenesis occurred in 84 % (agenesis 47 %; ectopic lingual 28
%; hypoplasia 9 %), normal-sized eutopic gland (“thyroid in situ”) was found in 10 % and
enlarged thyroid (dyshormonogenesis) was seen in 6 %.
Thyroid specific genes involved in CH are summarized in a table. In a cohort of 58 patients
PAX8 (exon 2 and exon 3) was analysed without deviation. Congenital malformations were
detected in 45 cases, and concomitant disorders in 46/210 CH patients.
Score system for predicting CH is proposed using signs (opened posterior fontanel, umbilical
hernia, dry skin, enlarged tongue, constipation, laziness, wide nasal bridge and prolonged
jaundice) and TSH value.
According to self-experience 10-15 μg/kg/day initial dose was administered in the last two
decades. Recently L-T4 and L-T3 combination was applied in some cases resulting in mostly
parallel decrease of elevated TSH and FT4 level.
The children with CH grow generally in a normal tempo but the disappearance of bone age
retardation is individual and may be protracted until 10 years of age. Bone mineral density
was measured first by single photon absorptiometry, later by peripheral quantitative computer
tomography, what may consider as a more precise method for pediatric use. Children with
CH detected by neonatal screening have very slightly decreased total BMD values comparing
to controls especially in prepubertal girls, but practically always within the reference range.
The final height of boys was found absolutely comparative with the reference values and the
decreasing deviation of the girls did not prove to be significant. The mean menarche age
corresponds to the Hungarian reference values in average, but not regarding its distribution.
This average derives from the values of two different subgroups characterised with an earlier
(< 12 yrs) and with a relative delayed (> 13 yrs) sexual development indicating the relationship
between the thyroid and sexual hormone axes.
In the 1980s we observed significant correlation between thyroglobulin levels and IQ values
detected lower IQ in athyroidism (Tg < 0,3 ng/ml). We presented ten years ago our experience
that the onset of L-T4 replacement during the first two weeks of life, the initial dose > 10 μg/kg/
day and the first T4 level > 3 μg/dl ensure the best IQ in prepubertal (8,5 ± 2,5 yrs) children.
In our recent study, using the Wechsler Intelligence Scale for children, it was found, that the
partial abilities – especially the performance and working memory – of the adolescents (14-16
yrs) are commonly decreased and the total Wechsler IQ is also tended to the low normal range
(93,25 ± 7,22).
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Despite these results the long-term outcomes of the children with CH may consider far better
than it was before the neonatal screening.
Finally, a few recent articles are recommended for more up-to-date information
[15,53,64,84-88].
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